This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Effect of Desmopressin on the Nocturnal Micturition Frequency in Patients With Parkinson Disease (DEPOPA)

This study has been terminated.
(lack of recruitment)
Information provided by:
Johannes Gutenberg University Mainz Identifier:
First received: December 9, 2008
Last updated: December 17, 2010
Last verified: June 2010
This study will be conducted to study the effect of Desmopressin on the nocturnal micturition frequency in patients with idiopathic Parkinson syndrome.

Condition Intervention Phase
Parkinson Disease Drug: Desmotabs Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Double Blind, Placebo Controlled, Randomized, Monocentre Cross-over Study to Investigate the Effect of Desmopressin on the Nocturnal Micturition Frequency in Patients With Parkinson Disease

Resource links provided by NLM:

Further study details as provided by Johannes Gutenberg University Mainz:

Primary Outcome Measures:
  • average nocturnal micturition frequency within the 2 weeks treatment phase each [ Time Frame: 6 weeks ]

Secondary Outcome Measures:
  • safety and efficacy on nocturnal micturition frequency of Desmopressin in patients with Parkinson syndrome [ Time Frame: 8 weeks ]

Enrollment: 1
Study Start Date: February 2009
Estimated Study Completion Date: February 2011
Estimated Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Desmopressin
Desmopressin 0,2 mg once daily and Desmopressin 0,2 mg bid for one week each.
Drug: Desmotabs
Desmotabs encapsulated, 0,2 mg once daily for one week, 0,2 mg bid for one week


Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male patients with idiopathic Parkinson Syndrome
  • 18 to 85 years
  • Nocturnal Pollakisuria > 2 mictions /night (documented in Screening phase )
  • Na+ i.S > 135 mmol/l
  • Patient is able to understand all aspects and individual consequences of the clinical trial
  • An informed consent signed and dated by the patient is available prior to any study specific treatment
  • The study is consistent with the patients´ request for an appropriate treatment

Exclusion Criteria:

  • Intake of the following concomitant medication: Carbamazepin, Oxcarbazepine, diuretics (Furosemide, Torasemide), non steroidal antiphlogistics, Loperamide, antidiuretic hormone analoga (besides study medication), drugs for treatment of bladder disfunction, in particular anticholinergics
  • Central Diabetes insipidus
  • Known heart insufficiency (NYHA Stad. III und IV)
  • clinical relevant kidney insufficiency
  • Habitual and psychogenic Polydipsia
  • Hypersensitivity or allergy against the trial medication or any other ingredient of the trial medication
  • Participation in another clinical trial during or within 6 months prior to this clinical trial
  • Medical or psychological condition, which might endanger the proper conduction of the clinical trial
  • Known drug or alcohol abuse
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00806468

Klinikum der Johannes Gutenberg-Universität Mainz, Studienzentrum Neurologie, Langenbeckstr. 1, 55131 Mainz
Mainz, Germany, 55131
Sponsors and Collaborators
Johannes Gutenberg University Mainz
Principal Investigator: Thomas Vogt, MD Johannes Gutenberg University Mainz, Department of Neurology
  More Information

Responsible Party: PD Dr. Thomas Vogt, Johannes Gutenberg University Mainz, Department of Neurology Identifier: NCT00806468     History of Changes
Other Study ID Numbers: DEPOPA-2008
Study First Received: December 9, 2008
Last Updated: December 17, 2010

Keywords provided by Johannes Gutenberg University Mainz:
Parkinson syndrome
Nocturnal polyuria in patients with Parkinson syndrome

Additional relevant MeSH terms:
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Deamino Arginine Vasopressin
Antidiuretic Agents
Natriuretic Agents
Physiological Effects of Drugs processed this record on September 19, 2017